Intravitreal PRN ranibizumab treatment for macular edemadue to branch retinal vein occlusion
- 1 January 2017
- journal article
- research article
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 47 (1) , 40-46
Abstract
Background/aim: To evaluate the effect of intravitreal pro re nata (PRN) ranibizumab treatment from the start on the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT) in macular edema (ME) due to branch retinal vein occlusion (BRVO). Materials and methods: Patients with ME secondary to BRVO, who were treated on a PRN basis after a single intravitreal ranibizumab injection, were retrospectively evaluated. The main outcome measures were changes in BCVA and CRT as measured by optical coherence tomography. Results: The number of injections over 6 months was 2.43 +/- 1.16. The mean BCVA of the patients was 0.84 +/- 0.10 logMAR at baseline and 0.41 +/- 0.06 at the 6th month (P < 0.001). Mean BCVA of the ischemic BRVO group was 1.06 +/- 0.68 logMAR at baseline and 0.44 +/- 0.30 logMAR at the 6th month (P < 0.05). Similarly, the mean BCVA of the nonischemic BRVO group was 0.77 +/- 0.53 logMAR at baseline and 0.41 +/- 0.36 logMAR at the 6th month (P < 0.05). Between groups, there was no significant difference in mean BCVA at any examination. Conclusion: Intravitreal ranibizumab is a safe and effective treatment option for ME due to ischemic and nonischemic BRVO using PRN from the start.Keywords
This publication has 31 references indexed in Scilit:
- Best practices for treatment of retinal vein occlusionCurrent Opinion in Ophthalmology, 2012
- Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein OcclusionOphthalmologica, 2011
- Antagonism of Vascular Endothelial Growth Factor for Macular Edema Caused by Retinal Vein Occlusions: Two-Year OutcomesOphthalmology, 2010
- Results of bevacizumab as the primary treatment for retinal vein occlusionsBritish Journal of Ophthalmology, 2010
- Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-upBritish Journal of Ophthalmology, 2010
- INTRAVITREAL RANIBIZUMAB (LUCENTIS) FOR BRANCH RETINAL VEIN OCCLUSION-INDUCED MACULAR EDEMARetina, 2010
- The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and AustraliaOphthalmology, 2010
- BEVACIZUMAB COMPARED WITH MACULAR LASER GRID PHOTOCOAGULATION FOR CYSTOID MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSIONRetina, 2009
- Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusionBritish Journal of Ophthalmology, 2008
- Errors in Retinal Thickness Measurements Obtained by Optical Coherence TomographyOphthalmology, 2006